share_log

Inari Medical (NASDAQ:NARI) Trading Down 6.7%

Inari Medical (NASDAQ:NARI) Trading Down 6.7%

稻田医疗(纳斯达克:NARI)股价下跌6.7%
Financial News Live ·  2022/09/17 08:22

Inari Medical, Inc. (NASDAQ:NARI – Get Rating) shares fell 6.7% during trading on Thursday . The stock traded as low as $73.00 and last traded at $73.70. 38,919 shares traded hands during trading, a decline of 96% from the average session volume of 865,388 shares. The stock had previously closed at $79.02.

稻田医疗股份有限公司(纳斯达克代码:NARI-GET评级)股价周四在交易中下跌6.7%。该股一度跌至73.00美元,最新报73.70美元。当日成交量为38,919股,较865,388股的平均成交量下降96%。该股此前收盘价为79.02美元。

Wall Street Analyst Weigh In

华尔街分析师也加入进来

Several research analysts recently issued reports on the company. Piper Sandler assumed coverage on Inari Medical in a research report on Tuesday, June 21st. They set an "overweight" rating and a $100.00 target price on the stock. Morgan Stanley dropped their target price on shares of Inari Medical from $108.00 to $93.00 and set an "overweight" rating on the stock in a research report on Friday, July 15th. BTIG Research decreased their price target on shares of Inari Medical from $130.00 to $100.00 and set a "buy" rating for the company in a report on Friday, June 24th. Canaccord Genuity Group upped their target price on Inari Medical from $92.00 to $94.00 and gave the company a "buy" rating in a research report on Friday. Finally, Canaccord Genuity Group boosted their price target on Inari Medical from $92.00 to $94.00 and gave the company a "buy" rating in a research note on Friday. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $94.71.

几位研究分析师最近发布了关于该公司的报告。派珀·桑德勒在6月21日星期二的一份研究报告中对Inari Medical进行了报道。他们为该股设定了“增持”评级和100.00美元的目标价。7月15日,摩根士丹利在一份研究报告中将稻日医疗的目标价从108.00美元下调至93美元,并对该股设定了“增持”评级。BTIG Research在6月24日星期五的一份报告中将Inari Medical的股票目标价从130.00美元下调至100.00美元,并将该公司的评级定为“买入”。Cancord Genuity Group在周五的一份研究报告中将Inari Medical的目标价从92.00美元上调至94.00美元,并给予该公司“买入”评级。最后,Canaccel Genuity Group在周五的一份研究报告中将Inari Medical的目标价从92.00美元上调至94.00美元,并给予该公司“买入”评级。一位研究分析师对该股的评级为持有,七位分析师对该公司股票的评级为买入。根据MarketBeat的数据,该股目前的平均评级为“适度买入”,共识目标价为94.71美元。

Get
到达
Inari Medical
伊纳里医疗
alerts:
警报:

Inari Medical Stock Down 5.6 %

Inari医疗类股下跌5.6%

The business has a 50 day moving average price of $75.43 and a 200 day moving average price of $75.70.

该业务的50日移动均线价格为75.43美元,200日移动均线价格为75.70美元。

Inari Medical (NASDAQ:NARI – Get Rating) last released its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.04. The business had revenue of $92.74 million for the quarter, compared to analyst estimates of $88.04 million. Inari Medical had a negative return on equity of 4.60% and a negative net margin of 4.47%. As a group, research analysts expect that Inari Medical, Inc. will post -0.67 EPS for the current fiscal year.
稻田医疗(纳斯达克:NARI-GET评级)最近一次发布季度收益数据是在8月3日星期三。该公司公布本季度每股收益(0.19美元),比普遍预期的(0.23美元)高出0.04美元。该业务本季度营收为9274万美元,而分析师预期为8804万美元。Inari Medical的净资产回报率为负4.60%,净利润率为负4.47%。作为一个整体,研究分析师预计Inari Medical,Inc.本财年每股收益将为0.67欧元。

Insider Activity at Inari Medical

Inari Medical的内幕活动

In other Inari Medical news, CEO William Hoffman sold 30,000 shares of the company's stock in a transaction dated Wednesday, July 6th. The shares were sold at an average price of $71.99, for a total value of $2,159,700.00. Following the completion of the transaction, the chief executive officer now owns 548,899 shares in the company, valued at $39,515,239.01. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Inari Medical news, CEO William Hoffman sold 30,000 shares of the firm's stock in a transaction that occurred on Wednesday, July 6th. The stock was sold at an average price of $71.99, for a total value of $2,159,700.00. Following the sale, the chief executive officer now directly owns 548,899 shares of the company's stock, valued at $39,515,239.01. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Andrew Hykes sold 5,000 shares of the stock in a transaction that occurred on Tuesday, September 6th. The shares were sold at an average price of $70.00, for a total value of $350,000.00. Following the transaction, the chief operating officer now owns 130,991 shares in the company, valued at approximately $9,169,370. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 155,204 shares of company stock worth $11,677,586. 11.90% of the stock is owned by company insiders.

在Inari Medical的其他消息中,首席执行官威廉·霍夫曼在7月6日星期三的一笔交易中出售了30,000股公司股票。这些股票的平均价格为71.99美元,总价值为2159,700.00美元。交易完成后,首席执行官现在拥有该公司548,899股,价值39,515,239.01美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,可以通过这个超级链接获得。在Inari Medical的其他消息中,首席执行官威廉·霍夫曼在7月6日星期三的一笔交易中出售了30,000股公司股票。这只股票的平均售价为71.99美元,总价值为2159,700.00美元。出售后,首席执行官现在直接持有548,899股公司股票,价值39,515,239.01美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,可以通过美国证券交易委员会网站访问该文件。此外,首席运营官安德鲁·海克斯在9月6日星期二的一次交易中出售了5000股该公司股票。这些股票的平均价格为70.00美元,总价值为350,000.00美元。交易完成后,首席运营官现在拥有该公司130,991股股票,价值约9,169,370美元。此次拍卖的披露信息可在此处找到。在上个季度,内部人士出售了155,204股公司股票,价值11,677,586美元。11.90%的股份由公司内部人士持有。

Institutional Trading of Inari Medical

Inari Medical的机构性交易

A number of institutional investors and hedge funds have recently modified their holdings of NARI. Advisor Group Holdings Inc. boosted its holdings in Inari Medical by 43.2% in the 4th quarter. Advisor Group Holdings Inc. now owns 1,683 shares of the company's stock worth $153,000 after buying an additional 508 shares during the last quarter. Bank of America Corp DE increased its position in shares of Inari Medical by 4.0% during the fourth quarter. Bank of America Corp DE now owns 101,868 shares of the company's stock worth $9,297,000 after purchasing an additional 3,918 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Inari Medical by 88.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 222,218 shares of the company's stock worth $20,282,000 after purchasing an additional 104,266 shares in the last quarter. Teacher Retirement System of Texas raised its stake in Inari Medical by 22.8% in the 4th quarter. Teacher Retirement System of Texas now owns 3,851 shares of the company's stock valued at $351,000 after purchasing an additional 715 shares during the last quarter. Finally, TD Asset Management Inc. lifted its holdings in Inari Medical by 87.7% in the 4th quarter. TD Asset Management Inc. now owns 50,603 shares of the company's stock valued at $4,619,000 after purchasing an additional 23,640 shares in the last quarter. Hedge funds and other institutional investors own 84.11% of the company's stock.

一些机构投资者和对冲基金最近调整了对Nari的持股。Advisor Group Holdings Inc.在第四季度增持了Inari Medical 43.2%的股份。Advisor Group Holdings Inc.现在持有1,683股该公司股票,价值15.3万美元,该公司在上个季度又购买了508股。第四季度,美国银行(Bank Of America Corp DE)将其在Inari Medical的股票头寸增加了4.0%。美国银行DE目前持有101,868股该公司股票,价值9,297,000美元,上一季度又购买了3,918股。Dimension Fund Advisors LP在第四季度将其在Inari Medical的股票头寸增加了88.4%。Dimension Fund Advisors LP在上个季度额外购买了104,266股票后,现在拥有222,218股该公司股票,价值20,282,000美元。德克萨斯州教师退休系统第四季度增持Inari Medical股份22.8%。德克萨斯州教师退休系统在上个季度额外购买了715股后,现在拥有3851股该公司股票,价值351,000美元。最后,TD Asset Management Inc.在第四季度增持了Inari Medical 87.7%的股份。TD Asset Management Inc.目前持有50,603股该公司股票,价值4,619,000美元,上一季度又购买了23,640股。对冲基金和其他机构投资者持有该公司84.11%的股票。

Inari Medical Company Profile

Inari医疗公司简介

(Get Rating)

(获取评级)

Inari Medical, Inc, a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism.

Inari Medical,Inc.是一家医疗设备公司,在美国开发、制造、营销和销售用于静脉疾病介入治疗的设备。该公司提供ClotTriever,这是一种机械血栓切除系统,旨在从大血管中取出、捕获和移除大血栓,以及用于治疗深静脉血栓;以及FlowTriever,这是一种基于大口径导管的抽吸和机械血栓切除系统,用于治疗肺血栓。

Recommended Stories

推荐故事

  • Get a free copy of the StockNews.com research report on Inari Medical (NARI)
  • 3 Banks Worth Considering For Q4
  • Stock Market: 3 Islands Of Strength In A Sea Of Red
  • MarketBeat: Week in Review 9/12 – 9/16
  • Is There a Cure for What is Ailing Teladoc Stock?
  • No One Told These 3 Stocks It's a Down Week
  • 免费获取StockNews.com关于稻田医疗(Nari)的研究报告
  • 第四季度值得考虑的3家银行
  • 股市:红海中的三座强国
  • MarketBeat:回顾一周9/12-9/16
  • 有什么办法可以治愈Teladoc股票的问题吗?
  • 没有人告诉这三只股票这是下跌的一周

Receive News & Ratings for Inari Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inari Medical and related companies with MarketBeat.com's FREE daily email newsletter.

接受Inari医学日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Inari Medical和相关公司的最新新闻和分析师评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发